Appeal No. 1997-3951
Application 08/238,987
claims 6 and 12 are not rejected in the Examiner’s Answer, it appears that the
examiner has withdrawn the rejection as to these two claims and accordingly, they
are no longer subject to this appeal.
Claims 1, 6, 8, and 12 are representative of the subject matter
encompassed by the pending claims and read as follows:
1. A composition for inhibition of tumor growth in a non-murine patient
comprising:
a pharmaceutical carrier containing an effective dosage of a compound
specifically blocking the Protein C anti-coagulation system selected from the group
consisting of anti-protein C antibodies, anti-protein S antibodies, inactivated
protein C and C4b binding protein in combination with a compound eliciting
production of cytokine in the patient, wherein the combination is in an effective
dosage to cause hemorrhagic necrosis of the tumor and the dosage of the
compound eliciting production of cytokine in the combination is not effective in the
absence of the Protein C blocking compound.
6. The composition of claim 1 wherein the compound eliciting production of
cytokines is endotoxin in a dosage stimulating production of tumor necrosis factor.
8. A method for inhibition of tumor growth in a patient comprising:
administering to a patient in need of treatment a compound specifically
blocking the Protein C pathway, wherein the compound is not a cytokine selected
from the group consisting of anti-protein C antibodies, anti-protein S antibodies,
inactivated protein C and C4b binding protein, in a dosage blocking the Protein C
anti-coagulation system and facilitating hemorrhagic necrosis of tumors, in
combination with a compound eliciting production of cytokines, wherein the
compound is not administered in a dosage effective to elicit hemorrhagic necrosis
of the microvasculated solid tumors.
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: November 3, 2007